Exhibit 99.2

Yantai Bohai Pharmaceuticals Group Co., Ltd.

Audited Financial Statements

Fiscal Years Ended June 30, 2009 and 2008

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To: The Board of Directors and Stockholders of Yantai Bohai Pharmaceuticals Group Co., Ltd.

We have audited the accompanying balance sheets of Yantai Bohai Pharmaceuticals Group Co., Ltd. (the “Company”) as of June 30, 2009 and 2008, and the related statements of income, stockholders’ equity and cash flows for each of the two years in the years ended June 30, 2009 and 2008. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audit in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of June 30, 2009 and 2008, and the results of its operations and its cash flows for each of the two years in the years ended June 30, 2009 and 2008, in conformity with accounting principles generally accepted in the United States of America.

/s/ Parker Randall CF (H.K.) CPA Limited

Parker Randall CF (H.K.) CPA Limited

Certified Public Accountants

Hong Kong

December 1, 2009

F-1

YANTAI BOHAI PHARMACEUTICALS GROUP CO., LTD.

BALANCE SHEETS AS OF JUNE 30, 2009 AND 2008

(Stated in US Dollars)

	Notes	2009		2008

ASSETS
Current assets
Cash and cash equivalents		$	2,491,726	$	781,282
Accounts receivable			11,070,129		8,918,209
Other receivables and prepayments	3		4,908,800		1,007,082
Inventories	4		307,834		1,049,191

Total current assets			18,778,489		11,755,764

Non-current assets
Property, plant and equipment, net	6		8,149,279		7,663,164
Intangible assets	5		17,298,720		17,227,872

Total non-current assets			25,447,999		24,891,036

TOTAL ASSETS			44,226,488		36,646,800

LIABILITES AND STOCKHOLDERS’ EQUITY
Current liabilities
Short-term borrowings	7		5,860,000		1,896,700
Accounts payable			971,208		3,065,389
Other accrued liabilities	8		2,785,672		5,254,040
Income taxes payable			677,666		598,190
Total current liabilities			10,294,546		10,814,319

STOCKHOLDERS’ EQUITY
Registered and Paid-in Capital	13		2,918,000		2,918,000
Capital reserve			5,836,000		5,836,000
Accumulated other comprehensive income			490,931		384,698
Statutory reserves	14		2,201,811		1,464,861
Retained earnings			22,485,200		15,228,922
Total stockholders’ equity			33,931,942		25,832,481

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY			44,226,488		36,646,800

See accompanying notes to the financial statements

F-2

YANTAI BOHAI PHARMACEUTICALS GROUP CO., LTD.

STATEMENT OF INCOME FOR THE YEARS ENDED JUNE 30, 2009 AND 2008

(Stated in US Dollars)

	Notes	2009			2008
		$			$

Sales			50,170,014			38,172,513

Less: Sales Tax			(821,400	)		(629,489	)

Net sales			49,348,614			37,543,024

Cost of sales			(7,975,267	)		(5,950,680	)

Gross profit			41,373,347			31,592,344

Selling, general and administrative expenses	9		(31,301,811	)		(22,601,932	)

Interest expenses	10		(184,404	)		(234,101	)

Operating income			9,887,132			8,756,311

Non-operating income			49,447			8

Non-operating costs			(36,366	)		(835	)

Income before taxes			9,900,213			8,755,484

Income taxes	11		(1,906,985	)		(2,303,712	)

Net income			7,993,228			6,451,772

See accompanying notes to the financial statements

F-3

YANTAI BOHAI PHARMACEUTICALS GROUP CO., LTD.

STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED JUNE 30, 2009 AND 2008

(Stated in US Dollars)

	Paid-in Capital		Capital reserve		Accumulated other comprehensive income		Statutory reserves		Retained earnings		Total

Balance, July 1, 2007	$	2,918,000	$	5,836,000	$	-	$	885,025	$	9,356,986	$	18,996,011

Net income for the year		-		-		-		579,836		5,871,936		6,451,772

Foreign currency translation adjustment		-		-		384,698		-		-		384,698

Balance, June 30, 2008		2,918,000		5,836,000		384,698		1,464,861		15,228,922		25,832,481

Net income for the year		-		-		-		736,950		7,256,278		7,993,228
Foreign currency
translation adjustment		-		-		106,233		-		-		106,233

Balance, June 30, 2009	$	2,918,000	$	5,836,000	$	490,931	$	2,201,811	$	22,485,200	$	33,931,942

See accompanying notes to the financial statements

F-4

YANTAI BOHAI PHARMACEUTICALS GROUP CO., LTD.

STATEMENT OF CASH FLOWS FOR THE YEARS ENDED JUNE 30, 2009 AND 2008

(Stated in US Dollars)

	2009			2008

Cash flows from operating activities
Net income	$	7,993,228		$	6,451,772
Adjustments to reconcile net income to net cash provided
by operating activities
Depreciation		302,762			283,417
Loss on disposals of property, plant and equipment		31,630			-
Changes in assets and liabilities
Increase in accounts receivable		(2,151,920	)		(1,885,681	)
(Increase)/decrease in other receivables and prepayments		(3,901,718	)		1,244,060
Decrease in inventories		741,357			655,446
(Decrease)/increase in accounts payable		(2,094,181	)		242,734
Decrease in accrued liabilities		(2,468,368	)		(4,786,934	)
Increase in income taxes payable		79,476			160,490

Net cash (used in)/provided by operating activities		(1,467,734	)		2,365,304

Cash flows from investing activities
Purchases of property, plant and equipment		(803,643	)		(80,647	)
Proceeds from disposals of property, plant and equipment		14,650			-

Net cash used in investing activities		(788,993	)		(80,647	)

Cash flows from financing activities
Proceeds of borrowings		5,860,000			1,896,700
Repayment of borrowings		(1,896,700	)		(4,085,200	)

Net cash provided by/(used in) financing activities		3,963,300			(2,188,500	)

Net increase in cash and cash equivalents		1,706,573			96,157

Effect of foreign currency translation on cash and cash equivalents		3,871			384,698

Cash and cash equivalents at beginning of year		781,282			300,427

Cash and cash equivalents at end of year		2,491,726			781,282

See accompanying notes to the financial statements

F-5

YANTAI BOHAI PHARMACEUTICALS GROUP CO., LTD.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FISCAL YEARS ENDED JUNE 30, 2009 AND 2008

1.	ORGANIZATION AND PRINCIPAL ACTIVITIES

Bohai Pharmaceuticals Group Co., Ltd. (the “Company” or “Bohai”) was incorporated in the People’s Republic of China (“PRC”) on July 8, 2004, with the principal business objective of development, production and distribution of medicine within PRC.

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Method of Accounting

The Company maintains its general ledger and journals with the accrual method accounting for financial reporting purposes. The financial statements and notes are representations of management. Accounting policies adopted by the Company conform to generally accepted accounting principles in the United States of America and have been consistently applied in the presentation of financial statements, which are compiled on the accrual basis of accounting.

(b) Basis of Presentation

The Company’s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

This basis of accounting differs in certain material respects from that used for the preparation of the books of account of the Company, which are prepared in accordance with the accounting principles and the relevant financial regulations applicable to enterprises with limited liabilities established in the PRC (“PRC GAAP”), the accounting standards used in the places of their domicile. The accompanying financial statements reflect necessary adjustments not recorded in the books of account of the Company to present them in conformity with US GAAP.

The Company’s operations are conducted in the PRC. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation, among other things.

(h) Fair value of Financial Instruments

The carrying values of the Company’s financial instruments, including cash and cash equivalents, accounts receivables, other receivables and prepayments, short-term borrowings, accounts payables, and other accrued liabilities their fair values due to the short-term maturity of such instruments.

(i) Intangible Assets

Intangible assets as “Pharmaceutical Formulas”, which acquired and with indefinite useful live are measured initially at cost and not subject to amortization shall be tested for impairment annually or more frequently if there is indication of impairment. If the carrying amount exceeds fair value, an impairment loss should be recognised. Subsequently reversal of a recognised impairment loss is prohibited.

F-6

(j) Property, plant and equipment

Property, plant and equipment, other than construction in progress, are stated at cost less depreciation and amortization and accumulated impairment loss. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its existing use. Maintenance, repairs and betterments, including replacement of minor items, are charged to expense; major additions to physical properties are capitalized.

Depreciation of property, plant and equipment is calculated to written off the cost , less their estimated residual value, if any, using the straight-line method over their estimated useful lives. The principal annual rates are as follows:-

Leasehold land and buildings	30 to 40 years
Motor vehicles	10 years
Plant and machinery	10 years
Office equipment	5 years

Upon sale or disposition, the applicable amounts of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or credited to income.

Construction in progress mainly represents expenditures in respect of the Company’s new corporate campus and machinery under construction. All direct costs relating to the acquisition or construction of the Company’s new corporate campus and machinery. Assets under construction are not depreciated until the construction is completed and the assets are ready for their intended use.

(k) Accounting for the Impairment of Long-Lived Assets

The Company adopted Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Live Assets” (“SFAS 144”), which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with SFAS 144. SFAS 144 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. Based on its review, the Company believes that, as of June 30, 2009 and 2008, there were no significant impairments of its long-lived assets.

(l) Foreign Currency Translation

The Company maintains its financial statements in the functional currency. The functional currency of the Company is the Renminbi (RMB). Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchanges rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income for the respective periods.

F-7

For financial reporting purposes, the financial statements of the Company which are prepared using the functional currency have been translated into United States dollars. Assets and liabilities are translated at the exchange rates at the balance sheet dates and revenue and expenses are translated at the average exchange rates and stockholders’ equity is translated at historical exchange rates. Any translation adjustments resulting are not included in determining net income but are included in foreign exchange adjustment to other comprehensive income, a component of stockholders’ equity.

	2009		2008
Year end US$: RMB exchange rate		6.82594		6.85401
Average periodic US$: RMB exchange rate		6.82594		7.26269

RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

(m) Revenue Recognition

Revenue represents the invoiced value of goods sold recognized upon the delivery of goods to customers. Revenue is recognized when all of the following criteria are met:

Persuasive evidence of an arrangement exists;

Delivery has occurred or services have been rendered;

The seller’s price to the buyer is fixed or determinable; and

Collectability is reasonably assured. Payments have been established.

(n) Cost of Revenue

Regarding the trading of medicine, the respective cost of revenue consists primarily of material cost, labor cost, overhead associated with the manufacturing process and related expenses which are directly attributable to the trading.

(o) Research and Development Costs

Research and development costs are charged as expense when incurred and included in operating expenses.

(p) Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of income and comprehensive income in the periods that includes the enactment date.

F-8

(q) Comprehensive Income

Comprehensive income is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, all items that are required to be recognized under current accounting standards as components of comprehensive income are required to be reported in a financial statement that is presented with the same prominence as other financial statements. The Company’s current components of other comprehensive income are the foreign currency translation adjustment.

(r) Commitments and Contingencies

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

(s) Recent Accounting Pronouncements

In March 2008, the FASB issued SFAS No. 161, DISCLOSURES ABOUT DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (an amendment to SFAS No. 133). This statement is effective for financial statements issued for fiscal year and interim periods beginning after November 15, 2008 and requires enhanced disclosures with respect to derivative and hedging activities. The Company will comply with the disclosure requirements of this statement if it utilizes derivative instruments or engages in hedging activities upon its effectiveness.

In April 2008, the FASB issued FASB Staff Position No. 142-3, DETERMINATION OF THE USEFUL LIFE OF INTANGIBLE ASSETS (“FSP No. 142-3”) to improve the consistency between the useful life of a recognized intangible asset (under SFAS No. 142) and the period of expected cash flows used to measure the fair value of the intangible asset (under SFAS No. 141(R)). FSP No. 142-3 amends the factors to be considered when developing renewal or extension assumptions that are used to estimate an intangible asset’s useful life under SFAS No. 142. The guidance in the new staff position is to be applied prospectively to intangible assets acquired after December 31, 2008. In addition, FSP No.142-3 increases the disclosure requirements related to renewal or extension assumptions. The Company does not believe implementation of FSP No. 142-3 have a material impact on its financial statements.

In May 2008, the FASB issued statement No. 162, THE HIERARCHY OF GENERALLY ACCEPTED ACCOUNTING PRINCIPLES. This statement identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles (GAAP) in the United States (the GAAP hierarchy). This statement is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, “the Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles”.

In May 2008, the FASB issued FSP Accounting Principles Board (“APB”) 14-1 “Accounting for Convertible Debt instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)” (“FSP APB 14-1”). FSP APB 14-1 requires the issuer of certain convertible debt instruments that may be settled in cash (or other assets) on conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer’s non-convertible debt borrowing rate. FSP APB 14-1 is effective for fiscal years beginning after December 15, 2008 on a retroactive basis. As we do not have convertible debt at this time, we currently believe the adoption of FSP APB 14-1 will have no effect on our combined results of operations and financial condition.

F-9

In May 2008, the FASB issued Statement No. 163, ACCOUNTING FOR FINANCE GUARANTEE INSURANCE CONTRACTS - AN INTERPRETATION OF FASB STATEMENT NO. 60. The premium revenue recognition approach for a financial guarantee insurance contract links premium revenue recognition to the amount of insurance protection and the period in which it is provided. For purposes of this statement, the amount of insurance protection provided is assumed to be a function of the insured principal amount outstanding, since the premium received requires the insurance enterprise to stand ready to protect holders of an insured financial obligation from loss due to default over the period of the insured financial obligation. This Statement is effective for financial statements issued for fiscal years beginning after December 15, 2008.

In June 2008, the FASB issued FASB Staff Position Emerging Issues Task Force (EITF) No. 03-6-1, DETERMINING WHETHER INSTRUMENTS GRANTED IN SHARE-BASED PAYMENT TRANSACTIONS ARE PARTICIPATING SECURITIES (“FSP EITF No. 03-6-1”). Under FSP EITF No. 03-6-1, unvested share-based payment awards that contain rights to receive nonforfeitable dividends (whether paid or unpaid) are participating securities, and should be included in the two-class method of computing EPS. FSP EITF No. 03-6-1 is effective for fiscal years beginning after December 15, 2008, and interim periods within those years, and is not expected to have a significant impact on the Company’s financial statements.

In April 2009, the FASB issued FSP 157-4, DETERMINING FAIR VALUE WHEN THE VOLUME AND LEVEL OF ACTIVITY FOR THE ASSET OR LIABILITY HAVE SIGNIFICANTLY DECREASED AND IDENTIFYING TRANSACTIONS THAT ARE NOT ORDERLY (“FSP 157-4”). FSP 157-4 provides additional guidance for estimating fair value in accordance with SFAS 157 when the volume and level of activity for the asset or liability have significantly decreased. FSP 157-4 also includes guidance on identifying circumstances that indicate a transaction is not orderly. FSP 157-4 is effective for interim and annual reporting periods ending after June 15, 2009, with early adoption permitted for periods ending after March 15, 2009. FSP 157-4 does not require disclosures for earlier periods presented for comparative purposes at initial adoption. In periods after initial adoption, FSP 157-4 requires comparative disclosures only for periods ending after initial adoption. The adoption of the provisions of FSP 157-4 is not anticipated to materially impact on the Company’s results of operations or the fair values of its assets and liabilities.

In May 2009, the FASB issued SFAS No. 165, SUBSEQUENT EVENTS (“SFAS 165”). SFAS 165 establishes general standards for accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or available to be issued and was effective for interim and annual periods ending after June 15, 2009. The adoption of SFAS No. 165 did not have an impact on the Company’s results of operations or financial condition. The Company evaluated all subsequent events that occurred from July 1, 2009 through September 30, 2009, inclusive, and does not found any material subsequent events are required to disclose.

In June 2009, the FASB issued SFAS No. 166 ACCOUNTING FOR TRANSFERS OF FINANCIAL ASSETS (“SFAS 166). This statement is intended to improve the relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial reports about a transfer of financial assets; the effects of a transfer on its financial position, financial performance, and cash flows; and a transferor’s continuing involvement in transferred financial assets. This Statement must be applied as of the beginning of each reporting entity’s first annual reporting period that begins after November 15, 2009, and is required to be adopted by the Company in the first quarter of fiscal year 2011. Earlier application is prohibited. This Statement must be applied to transfers occurring on or after the effective date. The Company does not expect the adoption of SFAS 166 to have a material impact on the Company’s financial position, results of operations and cash flows.

F-10

In June 2009, the FASB issued SFAS No. 168, THE FASB ACCOUNTING STANDARDS CODIFICATION AND THE HIERARCHY OF GENERALLY ACCEPTED ACCOUNTING PRINCIPLES (“SFAS No. 168”). SFAS No. 168 will become the single source of authoritative nongovernmental U.S. generally accepted accounting principles (“GAAP”), superseding existing FASB, American Institute of Certified Public Accountants, Emerging Issues Task Force (“EITF”), and related accounting literature. SFAS No. 168 reorganizes the thousands of GAAP pronouncements into roughly 90 accounting topics and displays them using a consistent structure. Also included is relevant Securities and Exchange Commission guidance organized using the same topical structure in separate sections. SFAS No. 168 will be effective for financial statements issued for reporting periods that end after September 15, 2009. The adoption of SFAS No. 168 is not expected to have a material impact on the Company’s consolidated results of operations and financial condition.

None of the above new pronouncements has current application to the Company, but may be applicable to the Company’s future financial reporting.

3.	OTHER RECEIVABLES AND PREPAYMENTS

Other receivables and prepayments as of June 30, 2009 and 2008 are consisted, of the following:

	2009		2008

Prepayment for advertising and promotion	$	1,736,025	$	45,958
Amount due from a equity holder		1,465,000		-
Loan to a third party		1,465,000		-
Loans interest receivable		18,459		-
Other receivables		224,316		961,124

	$	4,908,800	$	1,007,082

The amount due from an equity holder is unsecured, interest bearing at 3.93% per annum and has no fixed term of repayment.

Loan to a third party is unsecured, interest bearing at 4.32% per annum and repayable on November 11, 2009.

4.	INVENTORIES

Inventories as of June 30, 2009 and 2008 are consisted, of the following:

F-11

	2009		2008

Raw materials	$	250,405	$	716,303
Finished goods		57,429		332,888

Total inventories	$	307,834	$	1,049,191

5.	INTANGIBLE ASSETS

Intangible assets as of June 30, 2009 and 2008 are consisted, of the following:

	2009		2008

Pharmaceuticals formulas, at cost	$	17,298,720	$	17,227,872

F-12

6.	PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment as of June 30, 2009 and 2008 are consisted, of the following:

	Leasehold land and buildings		Plant and equipment			Office equipment		Motor vehicles			Total
At cost
Balance, July 1, 2007	$	7,416,710	$	932,466		$	11,050	$	277,210		$	8,637,436
Acquisition during the year		-		56,025			4,129		-			60,154

Balance, June 30, 2008		7,416,710		988,491			15,179		277,210			8,697,590
Acquisition during the year		-		232,554			59,459		295,610			587,623
Disposals		-		(68,553	)		-		(184,885	)		(253,438	)
Exchange difference		30,501		4,065			62		1,140			35,768

Balance, June 30, 2009	$	7,447,211	$	1,156,557		$	74,700	$	389,075		$	9,067,543

Accumulated depreciation
Balance, July 1, 2007	$	45,826	$	481,440		$	3,903	$	240,333		$	771,502
Charge for the year		183,306		90,099			2,053		7,959			283,417

Balance, June 30, 2008		229,132		571,539			5,956		248,292			1,054,919
Charge for the year		184,059		96,475			4,700		17,528			302,762
Disposals		-		(53,085	)		-		(154,073	)		(207,158	)
Exchange difference		942		2,350			25		1,021			4,338

Balance, June 30, 2009	$	414,133	$	617,279		$	10,681	$	112,768		$	1,154,861

Construction in progress
Balance, July 1, 2007	$	-	$	-		$	-	$	-		$	-
Additions		-		20,493			-		-			20,493
Transfer to plant and equipment		-		-			-		-			-

Balance, June 30, 2008		-		20,493			-		-			20,493
Additions		-		220,884			-		-			220,884
Transfer to plant and equipment		-		(4,864	)		-		-			(4,864	)
Exchange difference		-		84			-		-			84

Balance, June 30, 2009	$	-	$	236,597		$	-	$	-		$	236,597

Net book value
At June 30, 2009	$	7,033,078	$	775,875		$	64,019	$	276,307		$	8,149,279

At June 30, 2008	$	7,187,578	$	437,445		$	9,223	$	28,918		$	7,663,164

Depreciation expense for the year ended June 30, 2009 and 2008 were $302,762 and $283,417 respectively.

As of June 30, 2009 and 2008, the Company has pledged plant and machinery having a carrying amount of $562,331 and $Nil to secure a bank loan to the Company.

F-13

7.	SHORT-TERM BORROWINGS

The Company obtained several short-term loan facilities from financial institution in the PRC. Short-term borrowings as of June 30, 2009 are consisted, of the following:

Loan from

financial institution

Loan period

Annual

Interest

rate

Secured by

Amount

Shanghai Pudong

From Dec 12, 2008

6.6960

Haiyang

2,197,500

Development

to Dec 11, 2009

Construction

Limited

Industry Training

Centre and personal

guarantee by equity

holders

Yantai City

From Jan 20, 2009

6.9030

Yantai Hai Pu Can

1,318,500

Commercial Bank

to Jan 20, 2010

End Making Co. Ltd

Yantai Laishan

From Sep 27, 2008

9.3600

Yantai Ka Wah

293,000

Rural Credit Union

to Sep 26, 2009

Medical Equipment

Co. Ltd

Yantai Laishan

From Sep 27, 2008

12.2400

Company’s

586,000

Rural Credit Union

to Sep 26, 2009

machinery and

Vehicle

China Construction

From May 12, 2009

0.0000

Personal guarantee

1,465,000

Bank

to Nov 11, 2009

by equity holders

5,860,000

Short-term borrowings as of June 30, 2008 are consisted, of the following:

Loan from

financial institution

Loan period

Annual

interest

rate

Secured by

Amount

Yantai City

Commercial Bank

From Jan 31, 2008

to Jan 20, 2009

8.0925

Yantai Hai Pu Can

End Making Co. Ltd

1,313,100

Industrial and

From Jan 25, 2008

7.4700

Shan Dong Shui

583,600

Commercial Bank

to Jan 24, 2009

Hong Pharmaceutical

of China

Co. Ltd

1,896,700

F-14

8.	OTHER ACCRUED LIABILITIES

Other accrued liabilities as of June 30, 2009 and 2008 are consisted, of the following:

	2009		2008

Advanced from customers	$	-	$	735,680
Accrued selling expenses		1,677,026		321,717
Accrued staff costs		173,130		200,135
Value added tax payable		709,688		541,152
Amount due to a equity holder		-		108,426
Other taxes payable		77,374		58,863
Payable to Pharmaceutical formulas vendors		-		2,724,087
Other accrued expenses		148,454		563,980

	$	2,785,672	$	5,254,040

The amount due to an equity holder is unsecured, interest free, and has no fixed repayment terms.

9.	SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses for the years ended June 30, 2009 and 2008 are consisted, of the followings:

	2009		2008

Accommodation	$	5,151,876	$	4,593,639
Advertising and promotion		10,959,424		8,679,512
Audit fee		8,937		1,928
Commission		1,419,478		135,453
Conference		5,089,283		3,877,918
Depreciation		20,514		9,033
Staff costs		1,536,496		998,763
Traveling		2,755,259		1,649,162
Research and development cost		293,000		344
Other operating expenses		4,067,544		2,656,180

	$	31,301,811	$	22,601,932

10.	INTEREST EXPENSES

	2009		2008

Interest on short-term bank borrowings wholly repayable within one year	$	184,404	$	234,101

F-15

11.	INCOME TAXES

PRC Tax

PRC’s legislative body, the National People’s Congress, adopted the unified Enterprise Income Tax (“EIT”) Law on March 16, 2007. This new tax law replaces the existing separate income tax laws for domestic enterprises and foreign-invested enterprises and became effective on January 1, 2008. Under the new tax law, a unified income tax rate is set at 25% for both domestic enterprises and foreign-invested enterprises. However, there will be a transition period for enterprises, whether foreign-invested or domestic, that are currently receiving preferential tax treatments granted by relevant tax authorities. Enterprises that are subject to an enterprise income tax rate lower than 25% may continue to enjoy the lower rate and will transit into the new rate over a five year period beginning on the effective date of the EIT Law. Enterprises that are currently entitled to exemptions for a fixed term may continue to enjoy such treatment until the exemption term expires. Preferential tax treatments may continue to be granted to industries and projects that qualify for such preferential treatments under the new law.

	2009		2008

Income before tax	$	9,900,213	$	8,755,484

Income tax expense	$	1,906,985	$	2,303,712

The deferred tax asset and liability has not been recognized because of no valuation allowance to be established for the years ended June 30, 2009 and 2008.

12.	COMMITMENTS AND CONTINGENCIES

There are no foreseeable commitments or contingencies for the year ended June 30, 2009 and 2008.

13.	REGISTERED AND PAID-IN CAPITAL

Registered and Paid-in capital as of June 30, 2009 and 2008 is as follows:

	2009		2008

Registered and fully paid-in capital of RMB 20,000,000	$	2,918,000	$	2,918,000

14.	STATUTORY RESERVES

According to the laws and regulations in the PRC, the Company is required to provide for certain statutory funds, namely, reserve fund by an appropriation from net profit after taxes but before dividend distribution based on the local statutory financial statements of the PRC company prepared in accordance with the accounting principles and relevant financial regulations.

The Company in PRC is required to allocate at least 10% of its net profit to the reserve fund until the balance of such fund has reached 50% of its registered capital. Appropriation of enterprise expansion fund are determined at the discretion of it directors.

F-16

The reserve fund can only be used, upon approval by the relevant authority, to offset accumulated losses or increase capital. The enterprise expansion fund can only be used to increase capital upon approval by the relevant authority.

15.	FINANCIAL INSTRUMENTS

(a) Credit risk

The potential credit risk of the company is mainly attributable to its debtors and bank balances. In respect of debtors, the company has policies in place to ensure that it will only accept customers from countries which are politically stable and customers with an appropriate credit history. In addition, all the bank balances were made with financial institutions with high-credit quality. Thus, the company is not considered to be subject to significant credit risk.

(b) Interest rate risk

The company’s interest rate risk is primarily attributable to its short-term borrowings, loan to a third party and loan to equity holders. The company’s borrowings carry interest at fixed rate. The management has not used any interest rate swaps to hedge its exposure to interest rate risk.

All of the carrying amounts of the company’s financial assets and liabilities of short term maturities approximate their fair values.

F-17